HighTower Advisors LLC decreased its holdings in shares of Oracle Corporation (NYSE:ORCL - Free Report) by 4.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,193,021 shares of the enterprise software provider's stock after selling 50,115 shares during the quarter. HighTower Advisors LLC's holdings in Oracle were worth $163,802,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently bought and sold shares of ORCL. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Oracle by 0.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,680,278 shares of the enterprise software provider's stock valued at $2,151,395,000 after purchasing an additional 123,294 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Oracle in the second quarter worth approximately $1,911,930,000. Fisher Asset Management LLC lifted its position in shares of Oracle by 3.1% in the third quarter. Fisher Asset Management LLC now owns 13,670,982 shares of the enterprise software provider's stock worth $1,877,026,000 after purchasing an additional 409,531 shares in the last quarter. Amundi boosted its holdings in shares of Oracle by 1.5% during the second quarter. Amundi now owns 9,878,184 shares of the enterprise software provider's stock worth $1,447,648,000 after purchasing an additional 144,087 shares during the period. Finally, First Eagle Investment Management LLC boosted its holdings in shares of Oracle by 1.0% during the second quarter. First Eagle Investment Management LLC now owns 8,516,878 shares of the enterprise software provider's stock worth $1,248,148,000 after purchasing an additional 81,700 shares during the period. 42.44% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on ORCL shares. Barclays boosted their price objective on shares of Oracle from $250.00 to $252.00 and gave the company an "overweight" rating in a research report on Friday, September 11th. TD Cowen reiterated a "buy" rating and issued a $240.00 price objective on shares of Oracle in a research note on Thursday, October 29th. BMO Capital Markets cut their target price on shares of Oracle from $220.00 to $195.00 and set an "outperform" rating for the company in a research report on Friday, September 11th. JPMorgan Chase & Co. reissued a "buy" rating on shares of Oracle in a research note on Thursday, September 10th. Finally, Argus restated a "buy" rating and set a $225.00 price target on shares of Oracle in a report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, thirty-seven have assigned a Buy rating, five have assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $249.27.
Check Out Our Latest Stock Report on Oracle
Insider Buying and Selling
In related news, EVP Maria Smith sold 2,631 shares of the business's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $151.70, for a total value of $399,122.70. Following the completion of the sale, the executive vice president directly owned 64,357 shares in the company, valued at approximately $9,762,956.90. The trade was a 3.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Stephen Rusckowski bought 25,000 shares of the firm's stock in a transaction on Tuesday, September 29th. The shares were bought at an average cost of $139.35 per share, with a total value of $3,483,750.00. Following the transaction, the director directly owned 25,390 shares of the company's stock, valued at approximately $3,538,096.50. This trade represents a 6,410.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders sold 36,075 shares of company stock worth $5,342,123. 38.40% of the stock is currently owned by insiders.
Oracle Price Performance
NYSE ORCL opened at $114.99 on Wednesday. Oracle Corporation has a fifty-two week low of $109.21 and a fifty-two week high of $250.25. The stock's 50-day moving average is $134.91 and its two-hundred day moving average is $153.53. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.17 and a quick ratio of 1.17. The firm has a market cap of $347.71 billion, a P/E ratio of 18.02, a price-to-earnings-growth ratio of 0.83 and a beta of 1.79.
Oracle (NYSE:ORCL - Get Free Report) last announced its quarterly earnings results on Thursday, September 10th. The enterprise software provider reported $1.92 earnings per share for the quarter, topping analysts' consensus estimates of $1.74 by $0.18. The company had revenue of $19.34 billion during the quarter, compared to analysts' expectations of $19.13 billion. Oracle had a return on equity of 48.85% and a net margin of 26.36%. The business's quarterly revenue was up 29.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.47 earnings per share. Oracle has set its Q2 2027 guidance at 1.850-1.930 EPS and its FY 2027 guidance at 8.100-8.100 EPS. On average, analysts anticipate that Oracle Corporation will post 6.71 earnings per share for the current fiscal year.
Oracle Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, October 23rd. Investors of record on Friday, October 9th were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.7%. The ex-dividend date was Friday, October 9th. Oracle's payout ratio is 31.35%.
Recent Oracle Headlines
Here are a few of the latest headlines about ORCL:
- Positive Sentiment: Oracle Health won an expanded federal data-exchange role, and Shore Medical Center and Shore Physicians Group selected its AI-powered electronic health record system—evidence of customer adoption in healthcare. Article: Oracle Health federal data exchange expansion Article: Shore selects Oracle Health EHR
- Neutral Sentiment: One analyst reiterated a Buy rating despite Oracle’s share decline, arguing that its large backlog could support substantial upside. That view contrasts with investors’ concerns about the backlog’s customer concentration and the spending needed to fulfill it. Article: Analyst maintains Oracle Buy rating
- Negative Sentiment: Oracle’s sizable AI backlog is seen as a potential vulnerability because a large share is reportedly tied to OpenAI. That concentration raises questions about customer dependence and whether future revenue will justify the investment. Article: Oracle backlog and OpenAI concentration
Oracle Company Profile
(
Free Report)
Oracle Corporation is a technology company that develops and provides database software, cloud services, and enterprise applications. Its products help organizations manage data, run business operations, and build and deploy applications. Oracle's offerings include Oracle Database, Oracle Cloud Infrastructure, and cloud-based applications for functions such as finance, human resources, supply chain management, and customer experience. The company also provides software support, consulting, and related services.
Read More
Want to see what other hedge funds are holding ORCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oracle Corporation (NYSE:ORCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oracle, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oracle wasn't on the list.
While Oracle currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.